InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE:…
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
September 12, 2025 07:00 ET Â | Source: Cullinan Therapeutics, Inc. CAMBRIDGE, Mass.,…
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseqâ„¢ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker…
Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
MILAN, July 17, 2025 /PRNewswire/ --Â A recently published five-year pharmacovigilance study confirms…